Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660281 · ClinicalTrials.gov registry record · Phase 1
URMC Related Haplo-identical Donor BMT
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02660281: Completed Phase 1 study, sponsored by University of Rochester.
NCT02660281 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 74 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660281, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
Primary Outcome
The date of engraftment of ANC is the first of 3 consecutive days of ANC of 500 or higher. The date of engraftment of platelets is the first of 3 consecutive days of platelet counts of 20,000 or higher in the absence of platelet transfusions for at least 7 days prior.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- RADIATION Total Body Irradiation 1200 cGy
- DRUG Pre-Stem Cell Infusion Cyclophosphamide
- DRUG Pre-Stem Cell Infusion Mesna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-10 |
| Est. Completion | 2021-01-07 |
| Phase | Phase 1 |
What the finished NCT02660281 record still lists
NCT02660281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT02660281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02660281 about?
NCT02660281 is a clinical study titled "URMC Related Haplo-identical Donor BMT". This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
What is the current status of trial NCT02660281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2015-10. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT02660281?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Total Body Irradiation 1200 cGy (RADIATION), Pre-Stem Cell Infusion Cyclophosphamide (DRUG), Pre-Stem Cell Infusion Mesna (DRUG).
Who is sponsoring clinical trial NCT02660281?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02660281's enrollment target sits among peer trials
74 725th of 2000 higher than 1,269 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia